The Development and Commercialisation of Novel Antibiotic Compounds

传染病仍然是全球死亡的主要原因。新的疾病和耐多药细菌的不断增加表明，将继续需要具有优异活性和更好耐受性的新型抗菌疗法。然而，正在开发的抗生素化合物的数量少得令人担忧。Demuris筛选了一组独特的细菌分离株，并确定了三种潜在的新型抗生素。这个项目已经开发了这些化合物，从发现的早期阶段到化合物可以评估商业化和临床前开发的可行性。国家工业生物技术设施提供了Demuris目前无法获得的资源，使其能够生产足够数量的纯化化合物用于测试和开发目的。

Infectious diseases remain a leading cause of global deaths. New diseases and the continuous rise of multi-drug resistant bacteria suggest that there will be a continual need for novel antibacterial therapies with superior activity and better tolerance. However the number of antibiotic compounds in development is worryingly small.Demuris has screened a unique collection of bacterial isolates and has identified three potentially novel antibiotics. This project has developed these compounds from the early stages of discovery through to a point where the compounds can be evaluated for viability of commercialisation and pre-clinical development. The National Industrial Biotechnology Facility has provided the resources not currently available to Demuris and enabled the production of sufficient quantities of purified compounds for testing and development purposes.